# A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

Study · id `cardio:ct-nct03499704` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03499704](<https://clinicaltrials.gov/study/NCT03499704>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03499704

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.

## Technical summary

Registry record NCT03499704. Randomized; no masking; primary purpose treatment. Start 2020-02-11 (actual); primary completion 2024-01-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 133 participants (enrolled count; ClinicalTrials.gov record NCT03499704, source copy `cardio:ctgov-nct03499704-2026-03-18`, retrieved 2026-10-26)
- Started: 2020-02-11 (actual) (ClinicalTrials.gov record NCT03499704, source copy `cardio:ctgov-nct03499704-2026-03-18`, retrieved 2026-10-26)
- Primary completion: 2024-01-02 (actual) (ClinicalTrials.gov record NCT03499704, source copy `cardio:ctgov-nct03499704-2026-03-18`, retrieved 2026-10-26)
- Completion: 2024-01-16 (actual) (ClinicalTrials.gov record NCT03499704, source copy `cardio:ctgov-nct03499704-2026-03-18`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03499704, source copy `cardio:ctgov-nct03499704-2026-03-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03499704-2026-03-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
- Acronym: EPIDOTE
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Pioglitazone + Alogliptin
- Intervention (Drug): Alogliptin
- Intervention (Drug): Metformin
- Intervention (Drug): Dapagliflozin
- Lead sponsor: Celltrion Pharm, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)

## Provenance

Content hash: 74fd786735c14713897292a20e769f0f7f1d51d6ee7400655ad1404c724a6c00
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
